State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning

Joseph S. Ross, Cynthia Jackevicius, Harlan M. Krumholz, Jennifer Ridgeway, Victor Manuel Montori, G. Caleb Alexander, Judy Zerzan, Jiaquan Fan, Nilay D Shah

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

State Medicaid programs use preferred drug lists to help limit prescribing of high-cost drugs and, at the same time, to free providers from having to obtain prior authorization for a given prescription. We examined the impact of the Food and Drug Administration's May 2007 safety warning regarding rosiglitazone (Avandia), a diabetes drug found to raise the risk of heart attacks, on the drug's availability on state Medicaid preferred drug lists and on the prescribing of diabetes medications more generally for Medicaid beneficiaries. Nearly all state Medicaid programs covered rosiglitazone as a preferred drug, requiring no prior authorization, with minimal change after the safety warning. At the same time, the safety warning was associated with a greater-thanexpected decline in rosiglitazone prescribing among states providing coverage as a preferred drug. This suggests that providers reacted to the safety warning by reducing prescriptions. However, Medicaid programs that did provide coverage of rosiglitazone as a preferred drug still exhibited prescribing rates that were three to five times greater than rates in programs that did not provide coverage without prior authorization. We conclude that state Medicaid programs missed important opportunities to promote safer, more effective prescribing in the wake of the 2007 safety warning about rosiglitazone by making full use of preferred drug lists and prior authorization programs.

Original languageEnglish (US)
Pages (from-to)188-198
Number of pages11
JournalHealth Affairs
Volume31
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

rosiglitazone
Medicaid
Pharmaceutical Preparations
Safety
Prescriptions
Drug Costs
United States Food and Drug Administration

ASJC Scopus subject areas

  • Health Policy

Cite this

State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. / Ross, Joseph S.; Jackevicius, Cynthia; Krumholz, Harlan M.; Ridgeway, Jennifer; Montori, Victor Manuel; Alexander, G. Caleb; Zerzan, Judy; Fan, Jiaquan; Shah, Nilay D.

In: Health Affairs, Vol. 31, No. 1, 01.2012, p. 188-198.

Research output: Contribution to journalArticle

Ross, Joseph S. ; Jackevicius, Cynthia ; Krumholz, Harlan M. ; Ridgeway, Jennifer ; Montori, Victor Manuel ; Alexander, G. Caleb ; Zerzan, Judy ; Fan, Jiaquan ; Shah, Nilay D. / State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. In: Health Affairs. 2012 ; Vol. 31, No. 1. pp. 188-198.
@article{c456737e03124ec5b30d4f655a74b0fb,
title = "State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning",
abstract = "State Medicaid programs use preferred drug lists to help limit prescribing of high-cost drugs and, at the same time, to free providers from having to obtain prior authorization for a given prescription. We examined the impact of the Food and Drug Administration's May 2007 safety warning regarding rosiglitazone (Avandia), a diabetes drug found to raise the risk of heart attacks, on the drug's availability on state Medicaid preferred drug lists and on the prescribing of diabetes medications more generally for Medicaid beneficiaries. Nearly all state Medicaid programs covered rosiglitazone as a preferred drug, requiring no prior authorization, with minimal change after the safety warning. At the same time, the safety warning was associated with a greater-thanexpected decline in rosiglitazone prescribing among states providing coverage as a preferred drug. This suggests that providers reacted to the safety warning by reducing prescriptions. However, Medicaid programs that did provide coverage of rosiglitazone as a preferred drug still exhibited prescribing rates that were three to five times greater than rates in programs that did not provide coverage without prior authorization. We conclude that state Medicaid programs missed important opportunities to promote safer, more effective prescribing in the wake of the 2007 safety warning about rosiglitazone by making full use of preferred drug lists and prior authorization programs.",
author = "Ross, {Joseph S.} and Cynthia Jackevicius and Krumholz, {Harlan M.} and Jennifer Ridgeway and Montori, {Victor Manuel} and Alexander, {G. Caleb} and Judy Zerzan and Jiaquan Fan and Shah, {Nilay D}",
year = "2012",
month = "1",
doi = "10.1377/hlthaff.2011.1068",
language = "English (US)",
volume = "31",
pages = "188--198",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "1",

}

TY - JOUR

T1 - State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning

AU - Ross, Joseph S.

AU - Jackevicius, Cynthia

AU - Krumholz, Harlan M.

AU - Ridgeway, Jennifer

AU - Montori, Victor Manuel

AU - Alexander, G. Caleb

AU - Zerzan, Judy

AU - Fan, Jiaquan

AU - Shah, Nilay D

PY - 2012/1

Y1 - 2012/1

N2 - State Medicaid programs use preferred drug lists to help limit prescribing of high-cost drugs and, at the same time, to free providers from having to obtain prior authorization for a given prescription. We examined the impact of the Food and Drug Administration's May 2007 safety warning regarding rosiglitazone (Avandia), a diabetes drug found to raise the risk of heart attacks, on the drug's availability on state Medicaid preferred drug lists and on the prescribing of diabetes medications more generally for Medicaid beneficiaries. Nearly all state Medicaid programs covered rosiglitazone as a preferred drug, requiring no prior authorization, with minimal change after the safety warning. At the same time, the safety warning was associated with a greater-thanexpected decline in rosiglitazone prescribing among states providing coverage as a preferred drug. This suggests that providers reacted to the safety warning by reducing prescriptions. However, Medicaid programs that did provide coverage of rosiglitazone as a preferred drug still exhibited prescribing rates that were three to five times greater than rates in programs that did not provide coverage without prior authorization. We conclude that state Medicaid programs missed important opportunities to promote safer, more effective prescribing in the wake of the 2007 safety warning about rosiglitazone by making full use of preferred drug lists and prior authorization programs.

AB - State Medicaid programs use preferred drug lists to help limit prescribing of high-cost drugs and, at the same time, to free providers from having to obtain prior authorization for a given prescription. We examined the impact of the Food and Drug Administration's May 2007 safety warning regarding rosiglitazone (Avandia), a diabetes drug found to raise the risk of heart attacks, on the drug's availability on state Medicaid preferred drug lists and on the prescribing of diabetes medications more generally for Medicaid beneficiaries. Nearly all state Medicaid programs covered rosiglitazone as a preferred drug, requiring no prior authorization, with minimal change after the safety warning. At the same time, the safety warning was associated with a greater-thanexpected decline in rosiglitazone prescribing among states providing coverage as a preferred drug. This suggests that providers reacted to the safety warning by reducing prescriptions. However, Medicaid programs that did provide coverage of rosiglitazone as a preferred drug still exhibited prescribing rates that were three to five times greater than rates in programs that did not provide coverage without prior authorization. We conclude that state Medicaid programs missed important opportunities to promote safer, more effective prescribing in the wake of the 2007 safety warning about rosiglitazone by making full use of preferred drug lists and prior authorization programs.

UR - http://www.scopus.com/inward/record.url?scp=84855702842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855702842&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2011.1068

DO - 10.1377/hlthaff.2011.1068

M3 - Article

C2 - 22232110

AN - SCOPUS:84855702842

VL - 31

SP - 188

EP - 198

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 1

ER -